<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02172976</url>
  </required_header>
  <id_info>
    <org_study_id>NEPAFOX</org_study_id>
    <nct_id>NCT02172976</nct_id>
  </id_info>
  <brief_title>Randomized Multicenter Phase II/III Study With Adjuvant Gemcitabine Versus Neoadjuvant / Adjuvant FOLFIRINOX for Resectable Pancreas Carcinoma</brief_title>
  <official_title>Randomized Multicenter Phase II/III Study With Adjuvant Gemcitabine Versus Neoadjuvant/Adjuvant FOLFIRINOX in Resectable Pancreatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Krankenhaus Nordwest</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Krankenhaus Nordwest</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this multicenter study, patients with resectable pancreatic carcinoma will be treated with&#xD;
      (a) surgery followed by 6 cycles gemcitabine or (b) 4-6 cycles FOLFIRINOX followed by surgery&#xD;
      followed by 4-6 cycles FOLFIRINOX.&#xD;
&#xD;
      The overall survival between both therapies will be compared as well as other parameters.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase II/III randomized multicenter study. Patients with resectable pancreatic&#xD;
      carcinoma will be randomized in Arm A (surgery plus adjuvant gemcitabine, 6 cycles) or Arm B&#xD;
      (4-6 cycles FOLFIRINOX neoadjuvant, 4-6 cycles FOLFIRINOX adjuvant).&#xD;
&#xD;
      Primary endpoint is the overall survival, secondary endpoints are progression-free survival,&#xD;
      perioperative morbidity and mortality, rate of R0 resections, tolerability and feasibility of&#xD;
      neoadjuvant FOLFIRINOX and others.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2014</start_date>
  <completion_date type="Actual">May 2020</completion_date>
  <primary_completion_date type="Actual">January 2020</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>median overall survival</measure>
    <time_frame>From date of randomization until the date of death from any cause assessed up to 24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>median progression-free survival (PFS)</measure>
    <time_frame>From date of randomization until the date of first documented progression / relapse or date of death from any cause, whichever came first, assessed up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>perioperative morbidity and mortality</measure>
    <time_frame>30 days after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>R0 resection rate</measure>
    <time_frame>2 months after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pathological complete remission</measure>
    <time_frame>at surgery</time_frame>
    <description>during surgery, paraffin embedded tissue is prepared for analysis which is analyzed for remission grading at the central pathology afterwards</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adverse events (grade, number per patient) related to of G-CSF prophylaxis in the Folfirinox arm</measure>
    <time_frame>up to 40 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>prevalence of iron deficiency</measure>
    <time_frame>baseline, d1 of every cycle, end of treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Resectable Prancreas Carcinoma</condition>
  <arm_group>
    <arm_group_label>FOLFIRINOX</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oxaliplatin 85mg/m², Irinotecan 180mg/m², 5-FU 400mg/m² Bolus i.v., 5-FU continuous Infusion 2400 mg/m² Natriumfolinate 400mg/m² 46h d1; qd15 6 cycles pre- and 6 cycles post- surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gemcitabine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Gemcitabine 1000 mg/m² d1, d8, d15; qd 29; 6 cycles after surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <arm_group_label>Gemcitabine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <arm_group_label>FOLFIRINOX</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-Fluorouracil</intervention_name>
    <arm_group_label>FOLFIRINOX</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irinotecan</intervention_name>
    <arm_group_label>FOLFIRINOX</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Natriumfolinate</intervention_name>
    <arm_group_label>FOLFIRINOX</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histologically confirmed adenocarcinoma of the pankreas. For histological&#xD;
             confirmation, max. 3 tests are allowed. If no confirmation of carcinoma is possible,&#xD;
             the patient can not be included into the study.&#xD;
&#xD;
          2. Radiological confirmation of a locally limited curativ resectable (primarily resectale&#xD;
             or borderline situation) pankreas carcinoma without distant metastases.&#xD;
&#xD;
          3. no prior pancreas resection&#xD;
&#xD;
          4. no prior cytostatic chemotherapy&#xD;
&#xD;
          5. female and male patients &gt; 18 and &lt;=75 years using contraception&#xD;
&#xD;
          6. ECOG ≤ 1&#xD;
&#xD;
          7. medical resectability&#xD;
&#xD;
          8. granulocytes &gt; 1.500/µl&#xD;
&#xD;
          9. thrombocytes &gt; 100.000/µl&#xD;
&#xD;
         10. hemoglobin ≥ 8,0 g/dl&#xD;
&#xD;
         11. serumcreatinine ≤ 1.5x of normal value or Creatinine-Clearance &gt; 50 ml/min&#xD;
&#xD;
         12. written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Endocrine pancreas carcinoma&#xD;
&#xD;
          2. locally advanced inoperable stages: non-resectable infiltration of V. porta or longway&#xD;
             infiltration of A. mesenterica superior or infiltration of Truncus coeliacus.&#xD;
&#xD;
          3. distant metastases&#xD;
&#xD;
          4. Relapse&#xD;
&#xD;
          5. prior radiotherapy of measurable lesions&#xD;
&#xD;
          6. peritonealcarcinosis&#xD;
&#xD;
          7. malignant secondary disease, dated back &lt; 5 years (exeption: in-situ-carcinoma of the&#xD;
             cervix, adequately treated skin basal cell carcinoma)&#xD;
&#xD;
          8. contraindication for operative resection&#xD;
&#xD;
          9. ECOG ≥ 2&#xD;
&#xD;
         10. severe liver dysfunction (AST/ALT&gt;3,5xULN, AP&gt;6xULN)&#xD;
&#xD;
         11. Transhepatic drainage&#xD;
&#xD;
         12. active CHD (symptoms present), cardiomyopathy or heart insufficiency stage III-IV&#xD;
             according to NYHA and EF &lt; 45%&#xD;
&#xD;
         13. severe non-surgical accompanying diseases or acute infection&#xD;
&#xD;
         14. chronic diarrhea&#xD;
&#xD;
         15. chronic inflammable gastro-intestinal disease&#xD;
&#xD;
         16. peripheral polyneuropathy &gt; NCI grade II&#xD;
&#xD;
         17. pregnancy or lactation&#xD;
&#xD;
         18. hypersensibility or contraindication for Gemcitabine, Oxaliplatin, Natriumfolinate,&#xD;
             Irinotecan or 5-Fluorouracil&#xD;
&#xD;
         19. participation in another interventional trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Salah-Eddin Al-Batran, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute of Clinical Cancer Research (IKF), UCT - University Cancer Center, Frankfurt, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institute of Clinical Cancer Research (IKF), UCT - University Cancer Center, Frankfurt, Germany</name>
      <address>
        <city>Frankfurt</city>
        <zip>60488</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.ikf-nordwest.de/</url>
    <description>Related Info</description>
  </link>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>May 23, 2014</study_first_submitted>
  <study_first_submitted_qc>June 23, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 24, 2014</study_first_posted>
  <last_update_submitted>September 1, 2020</last_update_submitted>
  <last_update_submitted_qc>September 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pancreas cancer</keyword>
  <keyword>neoadjuvant chemotherapy</keyword>
  <keyword>Folfirinox</keyword>
  <keyword>gemcitabine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>No IPD will be shared</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

